)
)
)
Perseo pharma AG
Perseo Pharma is a biopharmaceutical company pioneering innovative metabolic therapies. The company has raised USD 12 million from private investors, including a U.S. patient advocacy organization and a corporate fund. We are currently raising our USD 9M Series A, for which we have signed a Term Sheet with a US investor.
Perseo's proprietary platform technology enables the development of highly effective gut-restricted treatments for a range of metabolic disorders. The company is targeting conditions like Exocrine Pancreatic Insufficiency (EPI) and a family of rare diseases made of Intoxication-Type Inborn Errors of Metabolism.
PER301, Perseo's lead compound for EPI (well established $1.5bn market in the US alone), is being developed in partnership with Nestlé Health Science. A significant commercial milestone for this collaboration was reached at the end of 2025.
What is your next catalyst (value inflection) update?
Phase Ib
Year Founded
2019
Lead Product in Development
PER301, Best-in-Class Pancreatic Enzyme Replacement Therapy
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3
CEO/Top Company Official
Dr. Yves Dudal, CEO
When you expect your next catalyst update?
DEC 2027
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
